Health2Sync, a digital therapeutics (DTx) platform specializing in diabetes care, announced on November 18 that it will officially list on the Taipei Exchange's Emerging Stock Board, marking its entry into the local capital market.
The company has achieved three major milestones in recent years. It became Taiwan's first artificial intelligence (AI) medical platform to expand overseas, it launched Taiwan's first DTx algorithm product approved by the Taiwan Food and Drug Administration (TFDA), and it has established deep partnerships with global pharmaceutical giants such as Sanofi, Novo Nordisk, and Abbott Laboratories.
Founded in 2013, Health2Sync completed its Series C funding round in 2024. Its major shareholders include Taiwania Capital, Be Health, and Cathay Venture, alongside strategic investments from electronics industry leaders Wistron and Pegatron.
Evolution into an AI smart medical platform
The company's main revenue comes from three segments. In the first half of 2025, pharmaceutical collaboration projects accounted for 40.4%, National Health Insurance (NHI) project revenue accounted for 35%, and medical device sales accounted for 22.1%. Currently, medical device revenue primarily comes from the distribution of Abbott's continuous glucose monitoring systems.
Health2Sync initially focused on digital health management for diabetes, launching the Diabetes Tracker application to help support daily patient self-care. It later integrated hardware with its long-accumulated database. It gradually evolved into an AI smart medical platform for chronic diseases, integrating the needs of hospitals, pharmaceutical companies, insurers, and government agencies. To date, the company has partnered with 400 medical institutions in Taiwan and 800 worldwide.
Asia's largest chronic disease management platform
Health2Sync's smart diabetes tracker application has amassed over 1.6 million users globally and collected 180 million health data points, making it Asia's largest chronic disease management platform. The company's three core products are the diabetes tracker application, a cloud-based care platform, and Insultrate, a software platform for insulin dose adjustment. In 2023, Insultrate received Class II medical device approval from the TFDA, making it Taiwan's first DTx algorithm product to receive such approval.
Taiwan's focus on chronic diseases driving demand
Health2Sync co-founder and CEO Ed Deng said the company is currently collaborating with international pharmaceutical giant Sanofi to secure NHI reimbursement for Insultrate's digital therapy, targeting approval in 2026. If successful, this will become a major driver of future revenue growth. Deng is also optimistic about the company's NHI benefits-related business's growth potential, forecasting that revenue could grow by 50% in 2026.
Deng highlighted that in recent years, Taiwan's National Health Insurance Administration (NHIA) has strengthened its focus on chronic diseases through policies like "Health Taiwan," which is gradually incorporating patients with high blood pressure, high blood sugar, and high cholesterol into digital care management. Additionally, following the COVID-19 pandemic, imbalances in healthcare education personnel, coupled with financial pressures on the NHI system, have increasingly driven demand for digital management of chronic diseases, including diabetes. He believes these factors will fuel tangible growth for the digital healthcare industry. Health2Sync is also optimistic about Taiwan's vibrant capital market, which is why the company has decided to go public and maintain its roots in Taiwan.
Expanding in international markets
Beyond attracting international pharmaceutical partners, Health2Sync is Taiwan's first medical AI startup to enter Japan's corporate health insurance market. In addition to Taiwan, its primary markets currently include Japan, Singapore, Australia, and South Korea.
Deng noted that given Health2Sync's market positioning and business model, there are currently no direct competitors in Asia. However, US-based Omada Health successfully listed on the Nasdaq Stock Exchange at a valuation of between US$1 billion and US$1.5 billion, demonstrating the promising outlook for the digital healthcare market. As Asia's largest chronic disease management platform, Health2Sync sees strong growth potential ahead.
Article edited by Jingyue Hsiao
